Trial Profile
Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Acronyms FAST
- 07 Apr 2022 Status changed from recruiting to completed.
- 26 Jul 2011 New trial record